Swings and roundabouts of VBP
This article was originally published in Scrip
Executive Summary
It looks as though drugs that get patients back to work quicker and those that tackle diseases affecting younger patients' quality of life could be winners under the UK's value-based pricing system. With just three months until VBP is supposed to be up and running, details have so far been elusive, but options of how the scheme may work are now being laid on the table.